Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3841321 | 0.89 | HDAC1 (0.37) | HDAC1HDAC6BACE1CD274CHRM2 | |
| SCHEMBL14287307 | 0.84 | HTR6 (0.39) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL14287263 | 0.84 | HTR6 (0.43) | HDAC1HDAC6CD274ALDH1A1MAPK1 | |
| SCHEMBL14287266 | 0.83 | HTR6 (0.41) | CD274ALDH1A1TSHRTP53MAPK1 | |
| SCHEMBL14287272 | 0.82 | ALDH1A1 (0.39) | ALDH1A1MEN1KMT2A | |
| SCHEMBL29805708 | 0.79 | MAOA (0.38) | ALDH1A1MAPT | |
| SCHEMBL4361494 | 0.79 | MAOA (0.38) | ALDH1A1MAPT | |
| SCHEMBL3845357 | 0.79 | ADORA2A (0.39) | — | |
| SCHEMBL3843574 | 0.79 | DRD2 (0.36) | HDAC1HDAC6ALDH1A1TSHRTP53 | |
| SCHEMBL6607897 | 0.78 | CYP2C9 (0.39) | ALDH1A1GAAMAPTKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1183025-B1 | INHIBITORS OF PROTON-GATED CATION CHANNELS AND THEIR USE IN THE TREATMENT OF ISCHAEMIC DISORDERS | PAINCEPTOR PHARMA CORP (CA) | 2009-01-14 | — | — | EP | disclosed |
| US-20080269230-A1 | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders | PAINCEPTOR PHARMA CORPORATION (CA) | 2008-10-30 | — | — | US | disclosed |
| US-7288653-B2 | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-10-30 | — | — | US | disclosed |
| US-20060079529-A1 | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders | PAINCEPTOR PHARMA CORPORATION (CA) | 2006-04-13 | — | — | US | disclosed |
| US-20040142936-A1 | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders | NEUROSEARCH A/S | 2004-07-22 | — | — | US | disclosed |
| US-6727260-B2 | USING COMPOUNDS CAPABLE OF INHIBITING THE ACTIVITY OF A PROTON-GATED CATION CHANNEL IN THERAPY OR ALEVIATION OF DISEASES OR DISORDERS ASSOCIATED WITH, OR MEDIATED BY A DROP IN EXTRACELLULAR PH | NEUROSEARCH A/S (DK) | 2004-04-27 | — | — | US | disclosed |
| US-20020058663-A1 | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders | AROS PHARMA APS (DK) | 2002-05-16 | — | — | US | disclosed |
| EP-1183025-A2 | INHIBITORS OF PROTON-GATED CATION CHANNELS AND THEIR USE IN THE TREATMENT OF ISCHAEMIC DISORDERS | NEUROSEARCH A/S (DK) | 2002-03-06 | — | — | EP | disclosed |
| WO-2000071102-A2 | INHIBITORS OF PROTON-GATED CATION CHANNELS AND THEIR USE IN THE TREATMENT OF ISCHAEMIC DISORDERS | NEUROSEARCH A/S (DK) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079529-A1 | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders | TRPV1, HVCN1, TRPM2 | HDAC1 855/4885HDAC6 335/4885BACE1 3809/4885 |
| US-20080269230-A1 | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders | TRPV1, HVCN1, TRPM2 | HDAC1 855/4885HDAC6 335/4885BACE1 3809/4885 |
| US-20020058663-A1 | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders | ASIC1, ASIC3, TRPM4 | HDAC1 824/4885HDAC6 264/4885BACE1 3819/4885 |
| US-20040142936-A1 | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders | TRPV1, HVCN1, TRPM2 | HDAC1 855/4885HDAC6 335/4885BACE1 3809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.